Starling Oncology Inc. (STLN)
STLN trades on Nasdaq in Health Care, Medical/Nursing Services. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/0001799191-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | STLN on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Nursing Services |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001799191 |
| SEC industry code | Services-Offices & Clinics of Doctors of Medicine |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $502.7M |
| Net income | -$60.6M |
| Operating income | -$36.1M |
| Net margin | -12.1% |
| Operating margin | -7.2% |
| Revenue growth | +27.8% |
| Cash | $33.6M |
| Total assets | $164.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "In connection with the preparation of the condensed consolidated financial statements as of September 30, 2026, the Company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance of such financial statements." | 10-Q 2026-11-06 |
| Cash and burn | $36.9M cash; operating cash flow $5.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 101,991,024 (2026-11-03); 98,381,340 a year earlier; 73,748,979 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest on 2025-03-25 | Source 2025-03-25 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-11-13 |
| Auditor | BDO USA, P.C., Costa Mesa, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $2.7M, sold $2.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $169.8M | -$15.7M | $10.1M | $36.9M | $72.5M | $620.4M | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $161.3M | -$9.8M | $11.9M | $41.1M | $79.9M | $587.2M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $147.4M | -$2.5M | -$2.2M | $30.3M | $78.6M | $545.8M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $142.0M | -$7.5M | $3.2M | $33.6M | $77.4M | $502.7M | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $136.6M | -$16.5M | -$12.6M | $27.7M | $76.2M | $461.0M | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $119.8M | -$17.0M | -$10.2M | $30.3M | $75.0M | $424.4M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $104.4M | -$19.6M | -$5.0M | $39.7M | $73.9M | $403.2M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $100.3M | -$13.2M | $4.0M | $49.7M | $93.1M | $393.4M | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2025-08-13 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report FORM 8-K | 8-K/A | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 552 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.3% |
| 1 month | -47.8% |
| 3 months | -44.1% |
| Year to date | -1.7% |
| 1 year | +13.6% |
| From 52-week high | -50.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Nursing Services
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AUNA | Auna SA | $4.63 | +0.87% | $342.7M |
| SRTA | Strata Critical Medical Inc. | $5.42 | -1.63% | $484.1M |
| SBC | SBC Medical Group Holdings Incorporated | $6.18 | -15.92% | $635.6M |
| OMDA | Omada Health Inc. | $14.49 | +1.12% | $898.9M |
| AHCO | AdaptHealth Corp. | $7.73 | +0.91% | $1.1B |
| PNTG | The Pennant Group Inc. Common Stock | $37.03 | +2.66% | $1.3B |
| INNV | InnovAge Holding Corp. | $9.58 | +1.16% | $1.3B |
| LFMD | LifeMD Inc. | $1.85 | -15.72% | $89.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier